| Abstract |
Objective: To investigate the correlation between clinical efficacy and serum inflammatory factor levels in patients with first-episode schizophrenia. METHODS: From December 2017 to December 2018, 90 patients with first-episode schizophrenia were enrolled. All patients were treated with olanzapine. Four weeks later, the positive and negative symptom scales (PANSS) were used to assess the status and detect transformation growth. Factor-β1 (TGF-β1), interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-1β (IL-1β), hypersensitive C-reactive protein (hs) -CRP). According to the PANSS reduction rate before and after treatment, the patients were divided into one group and two groups. The reduction rate of one group was less than 50%, and the reduction rate of the two groups was not less than 50%. TGF-β1, IL-6, IL-17, IL-1β, and hs-CRP were compared between the two groups. RESULTS: After 90 patients were treated with olanzapine for four weeks, 47 patients had a PNASS reduction rate of less than 50%, and 43 patients had a PNASS reduction rate of no less than 50%. After treatment, IL-6, IL-17, IL-1β were significantly lower than before treatment, and the data were significantly different (P<0.05). The hs-CRP after treatment was significantly increased compared with that before treatment. The data were significantly different (P <0.05). After treatment, IL-6, IL-17 and IL-1β were significantly lower than those before treatment, and one group of patients was significantly lower than the two groups. The difference between the two groups was statistically significant (P<0.05). After treatment, hs-CRP was significantly higher than that before treatment, and the difference was statistically significant (P<0.05). There was no significant difference between the two groups (P>0.05).Conclusion: After treatment with olanzapine in patients with first-episode schizophrenia, the changes of serum IL-6, IL-17 and IL-1β are obvious, which can reflect the therapeutic effect to some extent and evaluate the prognosis of patients.
|